Overcoming Akt Induced Therapeutic Resistance in Breast Cancer through siRNA and Thymoquinone Encapsulated Multilamellar Gold Niosomes

Molecular Pharmaceutics

Volumn 12, Issue 12, 2015, Pages 4214-4225

  Rajput, Shashi ^a   Puvvada, Nagaprasad ^a   Kumar, B N Prashanth ^a   Sarkar, Siddik ^b   Konar, Suraj ^a   Bharti, Rashmi ^a   Dey, Goutam ^a   Mazumdar, Abhijit ^c   Pathak, Amita ^a   Fisher, Paul B ^b   Mandal, Mahitosh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY   (India)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Akt siRNA; apoptosis; breast cancer; cell signaling; gold niosomes; thymoquinone

Indexed keywords

BIM PROTEIN; GOLD NANOPARTICLE; MACROGOL; MESSENGER RNA; NIOSOME; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; TAMOXIFEN; THYMOQUINONE; BENZOQUINONE DERIVATIVE; GOLD; NANOPARTICLE;

ALKALINITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CELL COUNT; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SOLUBILITY; DRUG UPTAKE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDRODYNAMICS; HYDROPHILICITY; HYDROPHOBICITY; IC50; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INTRACELLULAR SIGNALING; MCF 7 CELL LINE; MOLECULAR STABILITY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; STATIC ELECTRICITY; SURFACE CHARGE; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; SYNTHESIS; TUMOR MICROENVIRONMENT; ZETA POTENTIAL; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; BENZOQUINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GOLD; HUMANS; MCF-7 CELLS; NANOPARTICLES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; TAMOXIFEN;

EID: 84948987308     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00692     Document Type: Article

References (52)

1. Silva, J.; Cavazos, D. A.; Donzis, E.; Friedrichs, W. E.; Marciniak, R.; deGraffenried, L. A. Akt-induced tamoxifen resistance is associated with altered FKHR regulation Cancer Invest. 2007, 25 (7) 569-73 10.1080/07357900701513538
2. Cannings, E.; Kirkegaard, T.; Tovey, S. M.; Dunne, B.; Cooke, T. G.; Bartlett, J. M. Bad expression predicts outcome in patients treated with tamoxifen Breast Cancer Res. Treat. 2007, 102 (2) 173-9 10.1007/s10549-006-9323-8
3. Tokunaga, E.; Kimura, Y.; Mashino, K.; Oki, E.; Kataoka, A.; Ohno, S.; Morita, M.; Kakeji, Y.; Baba, H.; Maehara, Y. Activation of PI3K/Akt signaling and hormone resistance in breast cancer Breast Cancer 2006, 13 (2) 137-44 10.2325/jbcs.13.137
4. West, K. A.; Castillo, S. S.; Dennis, P. A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance Drug Resist. Updates 2002, 5 (6) 234-48 10.1016/S1368-7646(02)00120-6
5. Yoshimaru, T.; Komatsu, M.; Matsuo, T.; Chen, Y. A.; Murakami, Y.; Mizuguchi, K.; Mizohata, E.; Inoue, T.; Akiyama, M.; Yamaguchi, R.; Imoto, S.; Miyano, S.; Miyoshi, Y.; Sasa, M.; Nakamura, Y.; Katagiri, T. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells Nat. Commun. 2013, 4, 2443 10.1038/ncomms3443
6. Clark, A. S.; West, K.; Streicher, S.; Dennis, P. A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells Mol. Cancer Ther 2002, 1 (9) 707-17
7. McCubrey, J. A.; Steelman, L. S.; Abrams, S. L.; Lee, J. T.; Chang, F.; Bertrand, F. E.; Navolanic, P. M.; Terrian, D. M.; Franklin, R. A.; D'Assoro, A. B.; Salisbury, J. L.; Mazzarino, M. C.; Stivala, F.; Libra, M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance Adv. Enzyme Regul. 2006, 46, 249-79 10.1016/j.advenzreg.2006.01.004
8. Bellacosa, A.; Kumar, C. C.; Di Cristofano, A.; Testa, J. R. Activation of AKT kinases in cancer: implications for therapeutic targeting Adv. Cancer Res. 2005, 94, 29-86 10.1016/S0065-230X(05)94002-5
9. Sun, M.; Wang, G.; Paciga, J. E.; Feldman, R. I.; Yuan, Z. Q.; Ma, X. L.; Shelley, S. A.; Jove, R.; Tsichlis, P. N.; Nicosia, S. V.; Cheng, J. Q. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells Am. J. Pathol. 2001, 159 (2) 431-7 10.1016/S0002-9440(10)61714-2
10. Maroulakou, I. G.; Oemler, W.; Naber, S. P.; Tsichlis, P. N. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/Neu and MMTV-polyoma middle T transgenic mice Cancer Res. 2007, 67 (1) 167-177 10.1158/0008-5472.CAN-06-3782
11. Chau, N. M.; Ashcroft, M. Akt2: a role in breast cancer metastasis Breast Cancer Res. 2004, 6 (1) 55-57 10.1186/bcr739
12. Cheng, J. Q.; Lindsley, C. W.; Cheng, G. Z.; Yang, H.; Nicosia, S. V. The Akt/PKB pathway: molecular target for cancer drug discovery Oncogene 2005, 24 (50) 7482-92 10.1038/sj.onc.1209088
13. Meng, Q.; Xia, C.; Fang, J.; Rojanasakul, Y.; Jiang, B. H. Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway Cell. Signalling 2006, 18 (12) 2262-71 10.1016/j.cellsig.2006.05.019
14. Kumar, S.; Bryant, C. S.; Chamala, S.; Qazi, A.; Seward, S.; Pal, J.; Steffes, C. P.; Weaver, D. W.; Morris, R.; Malone, J. M.; Shammas, M. A.; Prasad, M.; Batchu, R. B. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells Mol. Cancer 2009, 8, 26 10.1186/1476-4598-8-26
15. Filleur, S.; Courtin, A.; Ait-Si-Ali, S.; Guglielmi, J.; Merle, C.; Harel-Bellan, A.; Clezardin, P.; Cabon, F. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth Cancer Res. 2003, 63 (14) 3919-22
16. Tolentino, M. J.; Brucker, A. J.; Fosnot, J.; Ying, G. S.; Wu, I. H.; Malik, G.; Wan, S.; Reich, S. J. Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization Retina 2004, 24 (1) 132-8 10.1097/00006982-200402000-00018
17. Yang, X. Z.; Du, J. Z.; Dou, S.; Mao, C. Q.; Long, H. Y.; Wang, J. Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery ACS Nano 2012, 6 (1) 771-81 10.1021/nn204240b
18. Yallapu, M.; Nagesh, P. B.; Jaggi, M.; Chauhan, S. Therapeutic Applications of Curcumin Nanoformulations AAPS J. 2015, 17, 1341-56 10.1208/s12248-015-9811-z
19. Sato, Y.; Hatakeyama, H.; Sakurai, Y.; Hyodo, M.; Akita, H.; Harashima, H. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo J. Controlled Release 2012, 163 (3) 267-76 10.1016/j.jconrel.2012.09.009
20. Mufamadi, M. S.; Pillay, V.; Choonara, Y. E.; Du Toit, L. C.; Modi, G.; Naidoo, D.; Ndesendo, V. M. A review on composite liposomal technologies for specialized drug delivery J. Drug Delivery 2011, 2011, 939851 10.1155/2011/939851
21. Puvvada, N.; Rajput, S.; Kumar, B. N. P.; Mandal, M.; Pathak, A. Exploring the fluorescence switching phenomenon of curcumin encapsulated niosomes: in vitro real time monitoring of curcumin release to cancer cells RSC Adv. 2013, 3 (8) 2553-2557 10.1039/c2ra23382g
22. Rajput, S.; Mandal, M. Antitumor promoting potential of selected phytochemicals derived from spices: a review Eur. J. Cancer Prev. 2012, 21 (2) 205-15 10.1097/CEJ.0b013e32834a7f0c
23. Tubesha, Z.; Abu Bakar, Z.; Ismail, M. Characterization and Stability Evaluation of Thymoquinone Nanoemulsions Prepared by High-Pressure Homogenization J. Nanomater. 2013, 2013, 6 10.1155/2013/453290
24. Pelicano, H.; Martin, D. S.; Xu, R. H.; Huang, P. Glycolysis inhibition for anticancer treatment Oncogene 2006, 25 (34) 4633-46 10.1038/sj.onc.1209597
25. Guo, S. T.; Huang, Y. Y.; Jiang, Q. A.; Sun, Y.; Deng, L. D.; Liang, Z. C.; Du, Q. A.; Xing, J. F.; Zhao, Y. L.; Wang, P. C.; Dong, A. J.; Liang, X. J. Enhanced Gene Delivery and siRNA Silencing by Gold Nanoparticles Coated with Charge-Reversal Polyelectrolyte ACS Nano 2010, 4 (9) 5505-5511 10.1021/nn101638u
26. Mintzer, M. A.; Simanek, E. E. Nonviral Vectors for Gene Delivery Chem. Rev. 2009, 109 (2) 259-302 10.1021/cr800409e
27. Feng, D.; Zhang, Y.; Shi, W.; Li, X.; Ma, H. A simple and sensitive method for visual detection of phosgene based on the aggregation of gold nanoparticles Chem. Commun. (Cambridge, U. K.) 2010, 46 (48) 9203-5 10.1039/c0cc02703k
28. Knowlden, J. M.; Hutcheson, I. R.; Jones, H. E.; Madden, T.; Gee, J. M.; Harper, M. E.; Barrow, D.; Wakeling, A. E.; Nicholson, R. I. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 2003, 144 (3) 1032-44 10.1210/en.2002-220620
29. Zhu, C. H.; Jung, S.; Luo, S. B.; Meng, F. H.; Zhu, X. L.; Park, T. G.; Zhong, Z. Y. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers Biomaterials 2010, 31 (8) 2408-2416 10.1016/j.biomaterials.2009.11.077
30. Venkatesan, P.; Puvvada, N.; Dash, R.; Kumar, B. N. P.; Sarkar, D.; Azab, B.; Pathak, A.; Kundu, S. C.; Fisher, P. B.; Mandal, M. The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer Biomaterials 2011, 32 (15) 3794-3806 10.1016/j.biomaterials.2011.01.027
31. Puvvada, N.; Kumar, B. N. P.; Konar, S.; Kalita, H.; Mandal, M.; Pathak, A. Synthesis of biocompatible multicolor luminescent carbon dots for bioimaging applications Sci. Technol. Adv. Mater. 2012, 13 (4) 045008 10.1088/1468-6996/13/4/045008
32. Dong, D. W.; Xiang, B.; Gao, W.; Yang, Z. Z.; Li, J. Q.; Qi, X. R. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells Biomaterials 2013, 34 (20) 4849-4859 10.1016/j.biomaterials.2013.03.018
33. Prashanth Kumar, B. N.; Rajput, S.; Bharti, R.; Parida, S.; Mandal, M. BI2536-A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells Biomed. Pharmacother. 2015, 74, 124-132 10.1016/j.biopha.2015.07.005
34. Puvvada, N.; Rajput, S.; Kumar, B. N.; Sarkar, S.; Konar, S.; Brunt, K. R.; Rao, R. R.; Mazumdar, A.; Das, S. K.; Basu, R.; Fisher, P. B.; Mandal, M.; Pathak, A. Novel ZnO hollow-nanocarriers containing paclitaxel targeting folate-receptors in a malignant pH-microenvironment for effective monitoring and promoting breast tumor regression Sci. Rep. 2015, 5, 11760 10.1038/srep11760
35. Sarkar, S.; Mazumdar, A.; Dash, R.; Sarkar, D.; Fisher, P. B.; Mandal, M. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells Cancer Biol. Ther. 2010, 9 (8) 592-603 10.4161/cbt.9.8.11103
36. Perumal, V.; Banerjee, S.; Das, S.; Sen, R. K.; Mandal, M. Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model Cancer Nanotechnol. 2011, 2 (1-6) 67-79 10.1007/s12645-011-0017-5
37. Rajput, S.; Kumar, B. N.; Sarkar, S.; Das, S.; Azab, B.; Santhekadur, P. K.; Das, S. K.; Emdad, L.; Sarkar, D.; Fisher, P. B.; Mandal, M. Targeted Apoptotic Effects of Thymoquinone and Tamoxifen on XIAP Mediated Akt Regulation in Breast Cancer PLoS One 2013, 8 (4) e61342 10.1371/journal.pone.0061342
38. Rajput, S.; Kumar, B. N.; Dey, K. K.; Pal, I.; Parekh, A.; Mandal, M. Molecular targeting of Akt by thymoquinone promotes G arrest through translation inhibition of Cyclin D1 and induces apoptosis in breast cancer cells Life Sci. 2013, 93, 783 10.1016/j.lfs.2013.09.009
39. Dey, K. K.; Pal, I.; Bharti, R.; Dey, G.; Kumar, B. N.; Rajput, S.; Parekh, A.; Parida, S.; Halder, P.; Kulavi, I.; Mandal, M. Identification of RAB2A and PRDX1 as the potential biomarkers for oral squamous cell carcinoma using mass spectrometry-based comparative proteomic approach Tumor Biol. 2015, 10.1007/s13277-015-3758-7
40. Hu, Y.; Xie, J.; Tong, Y. W.; Wang, C.-H. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells J. Controlled Release 2007, 118 (1) 7-17 10.1016/j.jconrel.2006.11.028
41. Sun, M.; Wang, G.; Paciga, J. E.; Feldman, R. I.; Yuan, Z. Q.; Ma, X. L.; Shelley, S. A.; Jove, R.; Tsichlis, P. N.; Nicosia, S. V.; Cheng, J. Q. AKT1/PKB alpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells Am. J. Pathol. 2001, 159 (2) 431-437 10.1016/S0002-9440(10)61714-2
42. Namgung, R.; Zhang, Y.; Fang, Q. L.; Singha, K.; Lee, H. J.; Kwon, I. K.; Jeong, Y. Y.; Park, I. K.; Son, S. J.; Kim, W. J. Multifunctional silica nanotubes for dual-modality gene delivery and MR imaging Biomaterials 2011, 32 (11) 3042-3052 10.1016/j.biomaterials.2010.12.018
43. Toshiyuki, M.; Reed, J. C. Tumor-Suppressor P53 Is a Direct Transcriptional Activator of the Human Bax Gene Cell 1995, 80 (2) 293-299 10.1016/0092-8674(95)90412-3
44. Jiang, P.; Du, W. J.; Heese, K.; Wu, M. The bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a bad/p53 complex at the mitochondria to induce apoptosis Mol. Cell. Biol. 2006, 26 (23) 9071-9082 10.1128/MCB.01025-06
45. Hemann, M. T.; Lowe, S. W. The p53-Bcl-2 connection Cell Death Differ. 2006, 13 (8) 1256-1259 10.1038/sj.cdd.4401962
46. Adams, J. M.; Cory, S. Life-or-death decisions by the Bcl-2 protein family Trends Biochem. Sci. 2001, 26 (1) 61-6 10.1016/S0968-0004(00)01740-0
47. Cory, S.; Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch Nat. Rev. Cancer 2002, 2 (9) 647-56 10.1038/nrc883
48. Danial, N. N.; Korsmeyer, S. J. Cell death: critical control points Cell 2004, 116 (2) 205-19 10.1016/S0092-8674(04)00046-7
49. Bagci, E. Z.; Vodovotz, Y.; Billiar, T. R.; Ermentrout, G. B.; Bahar, I. Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores Biophys. J. 2006, 90 (5) 1546-59 10.1529/biophysj.105.068122
50. Sabbatini, P.; McCormick, F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis J. Biol. Chem. 1999, 274 (34) 24263-9 10.1074/jbc.274.34.24263
51. Juven-Gershon, T.; Oren, M. Mdm2: the ups and downs Mol. Med. 1999, 5 (2) 71-83
52. Momand, J.; Wu, H. H.; Dasgupta, G. MDM2 - master regulator of the p53 tumor suppressor protein Gene 2000, 242 (1-2) 15-29 10.1016/S0378-1119(99)00487-4